Eliem Therapeutics, Inc. (ELYM)

USD 5.11

(-0.97%)

Market Cap (In USD)

342.67 Million

Revenue (In USD)

-

Net Income (In USD)

-35.11 Million

Avg. Volume

459.13 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.35-11.55
PE
-
EPS
-
Beta Value
-0.382
ISIN
US28658R1068
CUSIP
28658R106
CIK
1768446
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Employee Count
-
Website
https://www.eliemtx.com
Ipo Date
2021-08-10
Details
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.